政大機構典藏-National Chengchi University Institutional Repository(NCCUR):Item 140.119/33876
English  |  正體中文  |  简体中文  |  Post-Print筆數 : 27 |  全文筆數/總筆數 : 113648/144635 (79%)
造訪人次 : 51651711      線上人數 : 599
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋


    請使用永久網址來引用或連結此文件: https://nccur.lib.nccu.edu.tw/handle/140.119/33876


    題名: 學研機構研發成果商業化可行性評估機制之探討-以生物科技領域為例
    Feasibility Evaluation Mechanism for Commercialization of R&D Achievements in Academic and Research Institutes --- Focus on Biotechnology Field
    作者: 歐師維
    Ou, Shih Wei
    貢獻者: 劉江彬
    陳桂恆
    Liu, Paul C. B.
    Chen, Keith
    歐師維
    Ou, Shih Wei
    關鍵詞: 研發成果
    智慧財產
    商業化
    可行性評估
    生物科技
    國立陽明大學
    中央研究院
    工業技術研究院
    R & D Achievement
    Intellectual Property (IP)
    Commercialization
    Feasibility Evaluation Mechanism (FEM)
    Biotechnology
    National Yang-Ming University (NYMU)
    Academia Sinica
    Industrial Technology Research Institute (ITRI)
    日期: 2008
    上傳時間: 2009-09-17 18:41:36 (UTC+8)
    摘要: 學術研究機構向來是科技創新的主要動力來源，許多與人類生活息息相關的發明多半來自於學術研究機構此一孕育創新的搖籃。此外，一個國家的學術研究能量往往也反映了該國的技術能力與競爭力，因此世界各國無不投注大量資源於大專院校及研究機構，期望除了學術產出之外，亦能將原始的創新概念透過研發活動轉化為智慧財產，並進一步將其商業化，滿足市場需求，實現知識之最大價值。
    我國之學術研究能量並不落於美、歐、日等主要技術領先國之後，從我國政府投注於學術研發活動之經費、歷年發表於SCI、EI等期刊論文以及取得美國專利之數量等科技發展成果指標便可說明此點，然我國於1999年通過與美國拜杜法案意義相當之科技基本法至今已滿九年，各學研機構之專利申請量雖有成長之勢，然而2007年實際之智慧財產權收益卻僅佔研發總投入費用的0.87%；2005年全國技術貿易額收支比僅達0.23，與美、日、英等國相較，實可謂差強人意，顯見我國在研發成果商業化上已面臨一定瓶頸。
    在知識大爆炸方興未艾的二十一世紀，可以預見的是將有越來越多的研發成果持續產出，學研機構花費於取得並維護智慧財產之費用亦將持續提高，如何在產出的眾多研發成果及專利中，篩選出真正有商業化潛力之標的，以將有限的人力、時間、資金等資源投注於其上並轉化為實質的經濟效益，將是學研機構進行研發成果商業化時的重要課題；此外，在學研機構法人化之潮流下，若未來大學等學研單位須自行負擔大部份資金之籌措時，此一評估機制將更顯重要。另，在資訊高度不對稱的情況下，技術需求方難以辨認技術供給方之技術是否為適合之交易標的，因此若能建立一套商業化可行性評估機制，亦能使雙方間之資訊交流更為順暢，促進技術之移轉與商業化。
    因此，本研究嘗試提出一研發成果商業化可行性評估機制，以供學研機構進行內部評估，使國內「悶住」的研發能量得以透過有效的評估機制而活化。又，由於不同科技領域所適用之商業化可行性評估方式將有所差異，而生物科技領域為二十一世紀科技發展中之重要領域，且列為政府政策下的重點發展產業之一，加以作者本身之相關學經歷背景，是以本研究選擇生物科技領域研發成果為討論之重點。
    本研究分別從5W的角度來探討研發成果商業化可行性之評估機制，分別是進行商業化可行性評估之目的(Why)、進行商業化可行性評估之時點(When)、商業化可行性評估之執行者(Who)、評估所需資訊之取得(How)以及進行商業化可行性評估時所需考量之因素(What)，最後建立一研發成果商業化可行性評估機制，作為本研究之核心概念以及後續個案探討之依據。
    此外，本研究針對研發成果商業化可行性評估之各項構面進行介紹，並提出學研機構於進行評估時在各構面應考量之重要項目與問題。依所建立之評估機制與架構流程，將評估構面分為技術、智慧財產、市場、法規與財務五大構面，並以技術與智慧財產構面為探討之重點。
    由於本研究之研究對象為學術研究機構，且以生物科技領域為重心，故由大專院校、基礎研究機構及應用研究機構中各挑選一具代表性之單位作為個案研究對象，分別為國立陽明大學、中央研究院以及財團法人工業技術研究院，透過與各機構之研發成果管理專責單位進行訪談，深入了解其運作機制與現況，以期綜覽各類型學研機構之研發成果商業化可行性評估機制，並得出研究發現及建議。
    根據個案研究之發現，本研究對於國內學研機構之整體建議，主要包括：研發成果商業化可行性評估機制應依機構之目的、性質、智財管理現況加以擬定；研發成果商業化可行性評估之構面應配合研發成果之性質及開發階段而設定，並以技術構面為基礎，智財構面為樞紐連結市場與法規構面之評估，最後以財務構面進行統合；而學研機構若欲採外部審查方式執行評估工作，須考量可能之缺失；此外，研發成果商業化可行性之評估應由具備跨領域能力之團隊加以執行，並應使具備產業經驗與市場背景之人員有一定程度之涉入；再者，生物科技領域研發成果因其本質上之特殊性，故於進行商業化可行性評估時，有諸多因素需加以考量；最後，政府可主動協助建立專業之機構或團隊，提供學研機構進行研發成果商業化可行性評估甚至後續之技術行銷服務，以有效符合規模經濟、範疇經濟與專業、客觀之考量。
    Academic and research institutes are the origins of technology innovation. Many of the significant inventions were devised in these cradles of innovation. Academic and research power can often indicates the technology capability and competency of a nation. Every government invests vast resources to universities and research institutes in order not only to make academic publication but also to realize the maximum value of the knowledge through converting the innovative ideas into intellectual properties (IP) and further commercializing the R&D achievements to meet the market needs.

    The academic researches in Taiwan can compete with the technological leading countries such as the U.S, Japan, and E.U. countries, in terms of some science and technology indicators like R & D expenditure, SCI / EI publications, and the number of U.S. patent granted. Nevertheless, the actual revenue generated by IP in 2007 was only account for 0.87% of the total R&D input and the coverage ratio of technology balance of payments was only 0.23 in 2005. The fact indicates that there were some barriers on the path of R&D commercialization in Taiwan.

    In the 21st century of knowledge explosion, it is predictable that more and more R&D achievements will be generated from academic institutes and the expenses devoted to the acquisition and protection of IP will keep rising. Therefore, it will become a critical issue in academic institutes to sieve out the targets of the higher commercial potential from numerous R&D results and patents so as to concentrate the time, human and financial resources on those targets for its further commercialization. Moreover, under the highly asymmetrical information situation during the technology trading, technology buyers have difficulty in identifying whether the technology is a suitable trading target or not. A well-established feasibility evaluation mechanism will also stimulate the interflow of information and promote the technology transfer and commercialization.

    Accordingly, this thesis will try to establish a feasibility evaluation mechanism (FEM) for commercialization of R&D achievements in academic institutes in order to activate the stuffy R&D energy in Taiwan. Biotechnology is one of the most important fields of technology in the 21st century and thus be the main concern of the discussion of this thesis.

    This thesis will investigate the feasibility evaluation mechanism for commercialization of R&D achievements on a “5W” basis, including the purposes of evaluation (why), the time of evaluation (when), the executives of evaluation (who), the information needed in the evaluation process (how), and the factors that should be taken into consideration in the evaluation process (what). Accordingly, a feasibility evaluation mechanism for commercialization of R&D achievements will be established as the central concept of this study and as the ground of follow-up case analysis.

    In addition, each aspects of feasibility evaluation as well as the significant issues and questions of each aspect will be illustrated in this study. According to the feasibility evaluation mechanism and framework established in this study, there are five main evaluation aspects including the technical aspect, intellectual property aspect, market aspect, legal aspect, and financial aspect.

    The main subjects of this study were the academic institutes in biotechnology field in Taiwan, the National Yang-Ming University, the Academia Sinica, and the Industrial Technology Research Institute (ITRI). These institutes are chosen as the subjects of case study standing respectively for the higher education institute, basic research institute, and the applied research institute. By way of interviewing the personnel of R&D achievements and IPR management department in the institutes in question, the feasibility evaluation mechanism implemented by different types of academic institutes was investigated to delineate the key findings, followed up with some practical advices.

    The overall advices proposed by this study for the academic institutes in Taiwan were summarized as follows: (1) The feasibility evaluation mechanism for commercialization of R&D achievements should be devised in accordance with the purpose, the nature, and the IP management status of each institute. (2) The feasibility evaluation should be set to match up the development stage of the R&D achievements and take the technical aspect as the groundwork, IP aspect as the pivot connecting to the market and legal aspect, and the financial aspect as an integrated result. (3) Evaluation executed by external parties may be of some defects that should be taken into consideration. (4) The feasibility evaluation for R&D commercialization should be executed by multi-disciplinary team and the industry-experienced or market personnel should as well participate in the evaluation process. (5) Due to the characteristics of biotechnology, many special factors should be involved in the evaluation process. (6) The government may actively assist in setting up a professional organization or team to provide feasibility evaluation and even the further technology marketing services to meet the consideration of economies of scale/ scope, specialty, and objectivity.
    參考文獻: 中文文獻
    【專書】
     石井榮造(2008)，圖解行銷與市場分析，臺北市:大是文化。
     尹新天(2005)，專利權的保護，北京：知識產權出版社。
     李璞良譯(2004)，Martha Amram著，你的公司多值錢?如何創造與計算企業價值，台北：早安財經文化有限公司。
     吳雪舫(2005)，虎膽廟算之科技創業，高雄：于天網路印刷有限公司。
     周延鵬(2006)，一堂課2000億，台北：商訊文化事業股份有限公司。
     周延鵬(2006)，虎與狐的智慧力，台北：天下遠見出版股份有限公司。
     周文賢(1999)，行銷管理-市場分析與策略規劃，台北市:智勝文化。
     洪瑞章(2007)，專利侵害鑑定理論，台北：經濟部智慧財產局。
     徐小波(2006)，智慧財產商品化，台北：經濟部智慧財產局。
     陳隆麒等人譯(2001)，F. Peter Boer著，科技評價，台北：華泰文化。
     張作義等人譯(2001)，Vijay K. Jolly著，新技術的商業化-從創意到市場，北京：清華大學出版社。
     劉江彬、黃俊英(2004)，智慧財產管理總論，台北：華泰文化事業股份有限公司。
     蔣坡等(2007)，知識產權管理，北京：知識產權出版社。
     鄭成思(2003)，知識產權論(第三版)，北京: 法律出版社。
     謝銘洋(2007)，智慧財產法導論，台北：經濟部智慧財產局。
     2007生技產業白皮書，台北市: 經濟部工業局。
    【期刊、論文、專文】
     吳鎮安(2005)，技術商品化方案評選模式之研究，彰師大工業教育與技術研究所碩士論文。
     徐小波(2008)，公司經營及跨國投資策略之規劃-生技產品行銷策略及全球佈局。國立政治大學智慧財產研究所「生物科技研發成果商品化」課程授課資料。2008年4月15日。
     陳達仁(2007)，由專利看美國大學科技創新研發能量的表現，評鑑雙月刊，九十六年七月，第八期。第29頁至第35頁。
     黃謙銘(2001)，生物科技之評估及策略建議-以GnRH vaccine之專利、經營、學術三構面分析研究為例，國立政治大學科技管理研究所碩士論文。
     劉江彬(2007)，行政院產業人力套案---產業效益績效追蹤調查計畫(96年)子計畫三結案報告，國立政治大學智慧財產研究所。
     劉江彬(2008)，行政院產業人力套案---97年大專校院產學合作績效追蹤調查計畫，國立政治大學智慧財產研究所。
     劉江彬(2006)，生技臨床醫學之智慧財產權運作機制，行政院國家科學委員會專題研究計畫成果報告，國立政治大學智慧財產研究所
     鮑曄亭(2003)，專利拍賣可行性研究，國立交通大學科技管理研究所碩士論文。
     薛又軒(2002)，研發成果商品化-大學技轉中心運作模式之探討，國立中山大學企業管理研究所碩士論文。
    【網站】
     中央研究院研究成果發展管理要點。http://otl.sinica.edu.tw/index.php?t=21&article_id=7。
     國立陽明大學研發成果及技術移轉辦法。http://www.ym.edu.tw/rnd/ip/index.htm。
     國立清華大學研究成果技術移轉處理準則。http://140.114.39.237/law/law_2_2.html。
     科學技術統計要覽2007年版，台北，行政院國家科學委員會。http://www.nsc.gov.tw/tech/。
     科技統計名詞定義手冊(2004)，台北，行政院國家科學委員會。http://www.nsc.gov.tw/tech/。
     中文維基百科網頁，線上檢索日期：2008年4月11日，網址：http://zh.wikipedia.org/w/index.php?title=%E5%95%86%E5%93%81%E5%8C%96&variant=zh-tw。
     英文維基百科網頁，線上檢索日期：2008年4月11日，網址：http://en.wikipedia.org/wiki/Commercialization。
     英文維基百科。線上檢索日期：2008年5月1日。網址:http://en.wikipedia.org/wiki/Biotechnology。
     經濟部生物技術與醫藥工業發展推動小組全球資訊網。線上檢索日期：2008年5月1日。網址：http://www.biopharm.org.tw/2t2s/category.html。
     經濟部智慧財產局。網址: http://www.tipo.gov.tw/patent/patent_report/96%A6~%B1M%A7Q%B2%CE%ADp.pdf
     行政院衛生署，藥品臨床試驗申請須知。http://www.biopharm.com.tw/law/T/GCP/1.pdf
     財團法人高等教育評鑑中心基金會網站。網址：http://epaper.heeact.edu.tw/archive/2008/05/01/620.aspx。線上瀏覽日期：2008年9月1日。
     教育部電子報第307期。網址：http://epaper.edu.tw/e9617_epaper/topical.aspx?topical_sn=191。線上瀏覽日期：2008年9月2日。
     中央研究院網站。網址: http://www.sinica.edu.tw/。線上瀏覽日期: 2008年6月10日。
     中華民國97年度中央政府總預算，中央研究院單位預算。中央研究院編。http://proj1.sinica.edu.tw/~actweb/other/budget_ending/2008_02_29_11_20_19_97year_final.pdf。
     中央研究院公共事務組網站。網址: http://otl.sinica.edu.tw/index.php?v=5。線上瀏覽日期: 2008年6月10日。
     國立陽明大學網站。網址：http://www.ym.edu.tw/index.htm。線上瀏覽日期：2008年9月1日。
     中華民國專利法全文。http://law.moj.gov.tw/Scripts/Query4B.asp?FullDoc=%E6%89%80%E6%9C%89%E6%A2%9D%E6%96%87&Lcode=J0070007
     財團法人工業技術研究院網站。網址：http://www.itri.org.tw/chi/about/organization/index.asp?RootNodeId=080&NodeId=0803。線上瀏覽日期：2008年8月25日。
     經濟部智慧財產局網站。網址：http://www.tipo.gov.tw/ch/Download_DownloadPage.aspx?path=1647&Language=1&UID=10&ClsID=16&ClsTwoID=24&ClsThreeID=0。線上瀏覽日期：2008年8月26日。
     工研院專利交易平台網址：http://patentauction.itri.org.tw。
     許友耕(2005)，智慧財產權經營-工研院經驗分享簡報檔。資料來源：國立交通大學計算機與網路中心。網址：www.cc.nctu.edu.tw/~nctumot/%A5%CD%AA%AB%AC%EC%A7%DE/ppt/semianr0420.ppt。
    英文文獻
    【專書】
     Boer, F. P. (1999). The Valuation of Technology. J. Wiley & Sons, Inc., New York.
     Chesbrough, H. (2006). Open Business Models, Boston: Harvard Business School Press.
     Jolly, V. K. (1997). Commercializing New Technologies: Getting From Mind to Market. Boston: Harvard Business School Press
     Thore, S. and C. Bana e Costa (2002). Technology commercialization : DEA and related analytical methods for evaluating the use and implementation of technical innovation, Boston: Kluwer Academic Publishers.
     Udell, G. G. & Baker, K. G. (1982). How to Assess Before Your Invest. Long Beach, Calif: LOCUS.
     American Intellectual Property Law Association. AIPLA Report of the Economic Survery 2007.
    【期刊、論文、專文】
     Åstebro, T. (2003). Key Success Factors for R&D Project Commercialization. Working Papers -- University of Toronto Rotman School of Management.
     Åstebro, T., & Chen, G. (2003). The Statistical Accuracy of a Judgmental Process to Evaluate, Ex Ante, the Ex Post Commercial Success of Inventions. Working Papers -- University of Toronto Rotman School of Management.
     Bagchi-Sen, S. (2007). Strategic Considerations for Innovation and Commercialization in the US Biotechnology Sector. European Planning Studies, 15(6), 753-766.
     Benjamin, C. (2006). A framework for evaluating new technologies. International Journal of Technology Transfer & Commercialisation, 5(3), 1-1.
     Bill Barrett (2002). Defensive use of publications in an intellectual property strategy. Nature Biotechnology, 20, 191-193.
     Bill Barrett and Dave Crawford (2002). Integrating the intellectual property value chain. Nature Biotechnology, 20, BE43-BE46.
     Bowman-Upton, N., Seaman, S., & Sexton, D. (1989). INNOVATION EVALUATION PROGRAMS: DO THEY HELP THE INVENTORS? Journal of Small Business Management, 27(3), 23-30.
     Burnett, W., & Silverman, B. (1993). R&D project appraisal at the Gas Research Institute. Operations Research, 41(6), 1020.
     Craig S. Galbraith1, Sanford B. Ehrlich, and Alex F. DeNoble (2006). Predicting Technology Success: Identifying Key Predictors and Assessing Expert Evaluation for Advanced Technologies. Journal of Technology Transfer, 31, 673–684.
     Coe A Bloomberg (2005). Developing an intellectual property portfolio for the academic or not-for-profit institution. Nature Biotechnology, 23(1),119-121.
     Cukier, K. N. (2006). Navigating the future(s) of biotech intellectual property. Nature Biotechnology 24 (3), 249-251.
     D.A. Okongwu (1999). Evaluation And Assessment Of R&D Results And Inventions For Their Marketing And Commercialization. WIPO regional seminar on invention and innovation in Africa. Abidjan, September 1 to 3, 1999.
     Donald S. Siegela, David A. Waldman,Leanne E. Atwater, Albert N. Link (2003). Commercial knowledge transfers from universities to firms: improving the effectiveness of university–industry collaboration. Journal of High Technology Management Research, 14, 111–133.
     Gerrity, T. R. (2007). Partnering for Successful Technology Transfer. FLC Annual Meeting. Retrieved March 17, 2008, from Business Source Premier database.
     Guglielmi, M., Lascar, S., Mastrocola, V., & Williams, E. (2006).EVALUATING R&D WITH FIRST BOUNCE--LAST BOUNCE FRAMEWORK. Research Technology Management, 49(1), 44-50.
     Jerry G. Thursby & Marie C. (2002). Who Is Selling the Ivory Tower? Sources of Growth in University Licensing. Management Sceince, 48(1), 90-104.
     John V. Turner (1997), ASSESSMENT AND EVALUATION OF INVENTIONS AND THEIR COMMERCIALIZATION, WIPO AFRICAN REGIONAL SEMINAR FOR INVENTORS AND RESEARCHERS, Maseru, August 26 to 28, 1997.
     Lehrer, M., & Asakawa, K. (2004). Pushing Scientists into the Marketplace: PROMOTING SCIENCE ENTREPRENEURSHIP. California Management Review, 46(3), 55-76.
     Linton, J. D., Lombana, C. A. and A.D. Romig (2002).Accelerating Technology Transfer From Federal Laboratories to the private Sector—The Business Development. Engineering Management Journal , 13(3), 15-19.
     Marshall, W.G. (2004), Entrepreneurial Assessment of Technology Commercialization and New Venture Formation Using a Decision Matrix to Direct Commercialization Strategies.
     Matthews, Gale F. (2002). Intellectual property due diligence in biotechnology. The Licensing Journal.(2002-4-1).6-15.
     McAdam, M., Galbraith, B., McAdam, R., & Humphreys, P. (2006). Business Processes and Networks in University Incubators: A Review and Research Agendas. Technology Analysis & Strategic Management, 18(5), 451-472.
     Michael Batalia. Avant-Garde Technology Transfer at a Midsize, Private University. Association of University Technology Managers and Authors (AUTM) Technology Transfer Practice Manual 3rd Edition.Volume 2,Part 1,Chapter 2.2c, p5.
     Morgan Stanley Research. Valuing a Platform Biotech Company. October 15, 2002. p.23.
     P. Roussel, K. Saad, & T. Erickson(1991)，Third generation R&D. Harvard Business School Press.
     Powell, J and Moris, F (2004), Different Timelines for Different Technologies, Journal of Technology Transfer, 2004. 29: 125-152.
     Rahal, A., & Rabelo, L. (2006, December). Assessment Framework for the Evaluation and Prioritization of University Inventions for Licensing and Commercialization. Engineering Management Journal, 18(4), 28-36.
     Ravi, K Jain, Andrew O Martyniuk, Melinda M Harris, Rachel E Niemann, Karin Woldmann. (2003). Evaluating the commercial potential of emerging technologies. International Journal of Technology Transfer & Commercialisation, 2(1), 32-50.
     Robert E. Litan, Lesa Mitchell & E. J. Reedy. (2007). The University As Innovator. Issues in Science and Technology. 23(4),57-66.
     Rodriguez, Victor (2005). Material transfer agreements: open science vs. proprietary claims. Nature Biotechnology, 23(4), 489-491.
     Rogeer Hoedemaekers (2001). Commercialization, Patents and Moral Assessment of Biotechnology Products. Journal of Medicine and Philosophy. Vol. 26, No. 3, pp. 273-284.
     Rutherford, L., & Fulop, L. (2006). Commercialisation of university-based biotechnology research and internal performance issues for spin-offs. International Journal of Technology Transfer & Commercialisation, 5(1/2), 6-6.
     S.I. Cameron1, R.F. Smith1, and K.E. Kierstead (2005). Linking Medicinal=Nutraceutical Products Research with Commercialization. Pharmaceutical Biology, Vol. 43, No. 5, pp. 425–433.
     So Young Sohn, Tae Hee Moon.(2004).Decision Tree based on data envelopment analysis for effective technology commercialization. Expert Systems with Applications 26, 279–284.
     Stone, H., Iwamasa, K., Lundine, S., & Jasper, J. (2005). Picking winners: a framework for evaluating success potential of technology commercialisation. International Journal of Technology Transfer & Commercialisation, 4(3), 1-1.
     Vincent di Norcia. (2005). Intellectual Property and the commercialization of R&D. Science and Engineering Ethics, 11, 203-219.
     Walwyn, D. (2005). Selecting the most appropriate commercialisation strategy is key to extracting maximum value from your R&D. International Journal of Technology Transfer & Commercialisation, 4(2), 1-1.
     Walwyn, D. (2005). Selecting the most appropriate commercialisation strategy is key to extracting maximum value from your R&D. International Journal of Technology Transfer & Commercialisation, 4(2), 1-1.
    【網站】
     The Convention on Biological Diversity. http://www.cbd.int/
     OECD BIOTECHNOLOGY STATISTICS – 2006. http://www.oecd.org/dataoecd/51/59/36760212.pdf
     COMPENDIUM OF PATENT STATISTICS 2007. http://www.oecd.org/dataoecd/5/19/37569377.pdf
     National Science Foundation. http://www.nsf.gov/statistics/seind08/c6/tt06-22.htm
     美國各項專利規費一覽: http://www.uspto.gov/web/offices/ac/qs/ope/fee2007september30_2008may15.htm#maintain
     AUTM U.S. Licensing Activity Survey: Fiscal Year 2006. http://www.autm.net/events/file/AUTM_06_US%20LSS_FNL.pdf
     yet2.com website. http://www.yet2.com/app/about/home
     http://vivisimo.com/products/biometacluster
    描述: 碩士
    國立政治大學
    智慧財產研究所
    95361004
    97
    資料來源: http://thesis.lib.nccu.edu.tw/record/#G0095361004
    資料類型: thesis
    顯示於類別:[智慧財產研究所] 學位論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    100401.pdf82KbAdobe PDF21633檢視/開啟
    100402.pdf291KbAdobe PDF21745檢視/開啟
    100403.pdf219KbAdobe PDF21675檢視/開啟
    100404.pdf202KbAdobe PDF21858檢視/開啟
    100405.pdf399KbAdobe PDF22071檢視/開啟
    100406.pdf640KbAdobe PDF24891檢視/開啟
    100407.pdf746KbAdobe PDF23171檢視/開啟
    100408.pdf765KbAdobe PDF22776檢視/開啟
    100409.pdf850KbAdobe PDF22437檢視/開啟
    100410.pdf252KbAdobe PDF21845檢視/開啟
    100411.pdf172KbAdobe PDF22541檢視/開啟


    在政大典藏中所有的資料項目都受到原著作權保護.


    社群 sharing

    著作權政策宣告 Copyright Announcement
    1.本網站之數位內容為國立政治大學所收錄之機構典藏，無償提供學術研究與公眾教育等公益性使用，惟仍請適度，合理使用本網站之內容，以尊重著作權人之權益。商業上之利用，則請先取得著作權人之授權。
    The digital content of this website is part of National Chengchi University Institutional Repository. It provides free access to academic research and public education for non-commercial use. Please utilize it in a proper and reasonable manner and respect the rights of copyright owners. For commercial use, please obtain authorization from the copyright owner in advance.

    2.本網站之製作，已盡力防止侵害著作權人之權益，如仍發現本網站之數位內容有侵害著作權人權益情事者，請權利人通知本網站維護人員(nccur@nccu.edu.tw)，維護人員將立即採取移除該數位著作等補救措施。
    NCCU Institutional Repository is made to protect the interests of copyright owners. If you believe that any material on the website infringes copyright, please contact our staff(nccur@nccu.edu.tw). We will remove the work from the repository and investigate your claim.
    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋